Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016

Data Supplement

• Supplemental Data -

  Supplemental Table 1 - NDAs approved by the U.S. FDA from 2013 to 2016
  Supplemental Table 2 - Chemical structures of compounds within the NDAs approved in 2016 (ordered by approval date)
  Supplemental Table 3 -  Inhibition DDIs, NME as substrate
  Supplemental Table 4 - Induction DDIs, NME as substrate
  Supplemental Table 5 - Inhibition DDIs, NME as inhibitor
  Supplemental Table 6 - Induction DDIs, NMEs as inducers
  Supplemental Figure 1A - Therapeutic classes for inhibition DDIs with AUC ratios ≥ 5, NME as substrate (N = 14)
  Supplemental Figure 2A - Therapeutic classes for induction DDIs with AUC ratios ≤ 0.2, NME as substrate (N = 14)
  Supplemental Figure 3A - Therapeutic classes for inhibition DDIs with 2 ≤ AUC ratios < 5, NME as inhibitor (N = 11)